TTNP - Titan Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue15,0651,6713,646
Cost of Revenue---
Gross Profit15,0651,6713,646
Operating Expenses
Research Development6,1264,6754,075
Selling General and Administrative4,5963,7553,046
Non Recurring---
Total Operating Expenses---
Operating Income or Loss4,343-6,759-3,475
Income from Continuing Operations
Total Other Income/Expenses Net792-4,5201,072
Earnings Before Interest and Taxes5,135-11,279-2,403
Interest Expense---
Income Before Tax5,135-11,279-2,403
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops5,135-11,279-2,403
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income5,135-11,279-2,403
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares5,135-11,279-2,403